Morgan Stanley Exelixis, Inc. Transaction History
Morgan Stanley
- $1.36 Trillion
- Q1 2025
A detailed history of Morgan Stanley transactions in Exelixis, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,511,368 shares of EXEL stock, worth $106 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,511,368
Previous 2,752,573
8.76%
Holding current value
$106 Million
Previous $91.7 Million
1.16%
% of portfolio
0.01%
Previous 0.01%
Shares
23 transactions
Others Institutions Holding EXEL
# of Institutions
613Shares Held
257MCall Options Held
1.57MPut Options Held
730K-
Black Rock Inc. New York, NY33.5MShares$1.42 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA28.7MShares$1.21 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA22.5MShares$955 Million4.78% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny14.8MShares$628 Million0.88% of portfolio
-
State Street Corp Boston, MA11.8MShares$500 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $13.6B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...